Review the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.
Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.
With selective JAK inhibitors currently under investigation for AD, we could see greater efficacy without the safety tradeoffs of broad JAK inhibition.
Gain expert perspectives on the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.